Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (Plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

Key Takeaways

• REDEMPLO approved as first FCS therapy in Australia
• Phase 3 PALISADE showed median 80% triglyceride reduction
• Acute pancreatitis risk dropped 83% versus placebo
• Arrowhead aims global rollout using its TRiM siRNA platform

Pulse Analysis

Familial chylomicronemia syndrome (FCS) remains one of the most challenging lipid disorders, affecting roughly 1‑13 individuals per million worldwide. Patients experience triglyceride levels that can exceed 880 mg/dL, driving recurrent, often fatal pancreatitis and a cascade of metabolic complications. Traditional lipid‑lowering agents provide limited benefit, leaving a substantial unmet medical need for targeted therapies that can safely and sustainably reduce triglyceride burden.

REDEMPLO® (plozasiran) leverages Arrowhead’s proprietary TRiM™ platform to silence the APOC3 gene, curbing apoC‑III production and restoring normal triglyceride catabolism. The Phase 3 PALISADE study, spanning 39 sites and 75 adult participants, demonstrated a median 80% drop in fasting triglycerides and an 83% reduction in acute pancreatitis events compared with placebo. The Australian TGA’s priority‑review pathway, coupled with Breakthrough Therapy and Orphan Drug designations in the U.S., underscores the drug’s clinical promise and regulatory momentum, positioning REDEMPLO as a first‑in‑class option across multiple jurisdictions.

From a commercial perspective, the Australian approval expands Arrowhead’s global footprint and reinforces the viability of RNA interference therapeutics in rare disease markets. With the drug already cleared in the U.S., Canada, China, and pending European authorization, Arrowhead can pursue coordinated pricing and reimbursement strategies that reflect the high value of disease‑modifying outcomes. Moreover, the success of REDEMPLO bolsters confidence in the TRiM™ platform for upcoming Phase 3 programs targeting severe hypertriglyceridaemia, potentially unlocking broader applications of siRNA technology in cardiometabolic care.